The reiteration of an Overweight rating by a reputable analyst like Olivia Brayer from Cantor Fitzgerald is a positive signal for Biomarin Pharmaceutical. It suggests that the analyst believes the company's stock will outperform the market, which could lead to an increase in its stock price. The maintained price target of $120 also indicates that the analyst believes the stock is currently undervalued, which could attract more investors.